TY - JOUR
T1 - Comparative study of prophylactic cranial irradiation in patients with small cell lung cancer achieving a complete response
T2 - a long-term follow-up result
AU - Ohonoshi, Taisuke
AU - Ueoka, Hiroshi
AU - Kawahara, Shin
AU - Kiura, Katsuyuki
AU - Kamei, Haruhito
AU - Hiraki, Yoshio
AU - Segawa, Yoshihiko
AU - Hiraki, Shunkichi
AU - Kimura, Ikuro
PY - 1993/10
Y1 - 1993/10
N2 - Between 1981 and 1986, a total of 46 patients with small cell lung cancer (SCLC) achieving a complete response by chemotherapy with or without chest irradiation were randomized either to receive prophylactic cranial irradiation (PCI) or not. With a median follow-up time of 8.5 years for both groups, only five of 23 patients (22%) in the PCI group developed brain relapse, while 12 out of 23 (52%) in the no PCI group did so (P < 0.05). The frequency of patients developing a sole brain relapse during their whole clinical course was 4% for the PCI group and 17% for the no PCI group, however, the difference was not statistically significant. Patient survival was better for the PCI group (median survival time of 21 months, and 5-year survival rate of 22%) as compared with the no PCI group (median survival time of 15 months, and 5-year survival rate of 13%), showing a marginal significance (P = 0.097). Late neurologic toxicity was infrequent; only one developed a mild deterioration among seven long-term disease-free survivors in the PCI group. These results appear to warrant further clinical trials to clarify the utility of PCI in patients with SCLC achieving a complete response.
AB - Between 1981 and 1986, a total of 46 patients with small cell lung cancer (SCLC) achieving a complete response by chemotherapy with or without chest irradiation were randomized either to receive prophylactic cranial irradiation (PCI) or not. With a median follow-up time of 8.5 years for both groups, only five of 23 patients (22%) in the PCI group developed brain relapse, while 12 out of 23 (52%) in the no PCI group did so (P < 0.05). The frequency of patients developing a sole brain relapse during their whole clinical course was 4% for the PCI group and 17% for the no PCI group, however, the difference was not statistically significant. Patient survival was better for the PCI group (median survival time of 21 months, and 5-year survival rate of 22%) as compared with the no PCI group (median survival time of 15 months, and 5-year survival rate of 13%), showing a marginal significance (P = 0.097). Late neurologic toxicity was infrequent; only one developed a mild deterioration among seven long-term disease-free survivors in the PCI group. These results appear to warrant further clinical trials to clarify the utility of PCI in patients with SCLC achieving a complete response.
KW - Complete responders
KW - Prophylactic cranial irradiation
KW - Small cell lung cancer
UR - http://www.scopus.com/inward/record.url?scp=0027372518&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0027372518&partnerID=8YFLogxK
U2 - 10.1016/0169-5002(93)90308-K
DO - 10.1016/0169-5002(93)90308-K
M3 - Article
C2 - 8069603
AN - SCOPUS:0027372518
SN - 0169-5002
VL - 10
SP - 47
EP - 54
JO - Lung Cancer
JF - Lung Cancer
IS - 1-2
ER -